Press release

Press Release – 10.07.2017

Expansion of Echotherapy Reimbursement Coverage in Germany

Echopulse® Covered by French National Health Insurance for Breast Fibroadenomas

Theraclion achieves strong sales and accelerates its commercial development

FDA Authorized Immunotherapy and Echotherapy Combination Study on Breast Cancer

More than 1,000 treatments and changes in the distribution of Theraclion's capital

First direct comparison of echotherapy with Echopulse® to surgery results

Presentation of U.S. clinical data supporting Echotherapy with Echopulse® for breast fibroadenomas

THERACLION and Inner Mongolia Furui Medical Science Co., Ltd sign Joint Venture in China

Positive long-term Echopulse® results in breast fibroadenoma

Theraclion announces first Asian study demonstrating results in large thyroid nodules